NCT06649253Recruiting
Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse
REALL CD9 : Molecular Mechanisms Involved in Relapses of Childhood B-acute Lymphoblastic Leukaemia, Role of Non-coding RNA in CD9 Gene Regulation
Source: ClinicalTrials.gov · Last updated 2 Jan 2026
Brief summary (registry, in English)
B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 15 Oct 2024
- Start date
- 22 Mar 2025
- Primary completion date
- 30 Apr 2035
- Lead sponsor
- Rennes University Hospital
- NCT number
- NCT06649253
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 22 Mar 2025 to the primary completion date, 30 Apr 2035
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Patient of childbearing age without effective contraception.
Other
- Isolated extramedullary involvement at inclusion
- Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.
Who the study is looking for
- Under 18 years
- With established diagnosis of B-ALL
- Initial diagnosis made in the investigating centre
- Having received oral and written information about the protocol, or oral only if the patient is unable to read.
- Having signed a consent form if the patient is capable of giving informed written consent.
- Whose legal guardians have received oral and written information about the protocol, and have signed a free, informed and written consent.
- Beneficiary of a social security scheme
Age in the registry: 0 years to 17 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Angers Coordinator of this site? Confirm its status | Angers | France | Recruiting |
| Chu Brest Coordinator of this site? Confirm its status | Brest | France | Recruiting |
| CHU Rennes Coordinator of this site? Confirm its status | Rennes | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.